ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AEE788. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

33 träffar

Bibliografisk träff 2019-08-06

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.

He J, McLaughlin RP, van der Noord V, Foekens JA, Martens JWM, van Westen G, Zhang Y, van de Water B.

Breast Cancer Res Treat · research-article; journal article · DOI 10.1007/s10549-019-05380-z

Bibliografisk träff 2019-01-31

Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and <i>Abcb1/Abcg2</i>-Deficient Mice.

Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF.

Drug Metab Dispos · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/dmd.118.084210

Bibliografisk träff 2017-02-28

AEE788 Inhibits Basal Body Assembly and Blocks DNA Replication in the African Trypanosome.

Sullenberger C, Piqué D, Ogata Y, Mensa-Wilmot K.

Mol Pharmacol · research-article; journal article · DOI 10.1124/mol.116.106906

Bibliografisk träff 2015-06-24

Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells.

Valverde A, Peñarando J, Cañas A, López-Sánchez LM, Conde F, Hernández V, Peralbo E, López-Pedrera C, de la Haba-Rodríguez J, Aranda E, Rodríguez-Ariza A.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0131363

Bibliografisk träff 2014-01-27

New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.

Behera R, Thomas SM, Mensa-Wilmot K.

Antimicrob Agents Chemother · research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.01691-13

Bibliografisk träff 2012-09-26

Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.

Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH.

Clin Cancer Res · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-12-1499

Bibliografisk träff 2012-08-24

AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.

Venkatesan P, Bhutia SK, Singh AK, Das SK, Dash R, Chaudhury K, Sarkar D, Fisher PB, Mandal M.

Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.lfs.2012.08.024

Bibliografisk träff 2012-03-07

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK.

Cancer Chemother Pharmacol · research-article; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1854-6

Bibliografisk träff 2011-10-09

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-011-1754-1

Bibliografisk träff 2010-11-01

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.

Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, Schlegel J.

Int J Mol Med · research support, non-u.s. gov't; journal article · DOI 10.3892/ijmm_00000518

Bibliografisk träff 2010-10-15

Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.

Wedel S, Hudak L, Seibel JM, Juengel E, Oppermann E, Haferkamp A, Blaheta RA.

Prostate · journal article · DOI 10.1002/pros.21288

Bibliografisk träff 2010-10-01

Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma.

Meco D, Servidei T, Zannoni GF, Martinelli E, Prisco MG, de Waure C, Riccardi R.

Transl Oncol · research-article; journal article · DOI 10.1593/tlo.10163

Bibliografisk träff 2010-07-20

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res · journal article · DOI 10.1158/1541-7786.mcr-09-0388

Bibliografisk träff 2010-04-07

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exphem.2010.03.017

Bibliografisk träff 2010-04-01

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6605641

Bibliografisk träff 2010-02-12

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats.

Deng M, Huang H, Jin H, Dirsch O, Dahmen U.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-010-9394-6

Bibliografisk träff 2010-01-19

Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model.

Deng M, Huang H, Dirsch O, Dahmen U.

Eur Surg Res · research support, non-u.s. gov't; journal article · DOI 10.1159/000275818

Bibliografisk träff 2009-11-10

Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques.

Venkatesan P, Das S, Krishnan MM, Chakraborty C, Chaudhury K, Chaudhury K, Mandal M.

Micron · research support, non-u.s. gov't; journal article · DOI 10.1016/j.micron.2009.10.008

Bibliografisk träff 2009-07-07

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.

Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, Jonas D, Blaheta RA.

BJU Int · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1464-410x.2009.08759.x

Bibliografisk träff 2009-05-27

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L, Jonas D, Blaheta RA.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-9-161

Bibliografisk träff 2008-10-01

The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice.

Okamoto K, Neureiter D, Alinger B, Meissnitzer M, Sass G, Schmitz V, Di Fazio P, Wissniowski T, Gahr S, Hohenstein B, Kaufmann B, Schlösser A, Haus U, Hahn EG, Herold C, Ocker M.

Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo_00000059

Bibliografisk träff 2008-09-01

[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].

Wedel SA, Mickuckyte A, Juengel E, Jones J, Hudak L, Jonas D, Blaheta RA.

Urologe A · journal article · DOI 10.1007/s00120-008-1831-1

Bibliografisk träff 2008-03-11

Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models.

Huamani J, Willey C, Thotala D, Niermann KJ, Reyzer M, Leavitt L, Jones C, Fleishcher A, Caprioli R, Hallahan DE, Kim DW.

Int J Radiat Oncol Biol Phys · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ijrobp.2007.12.049

Bibliografisk träff 2008-01-28

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.0709662105

Bibliografisk träff 2007-09-01

Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models.

Oehler-Jänne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, Vuong V, Pruschy M.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-07-0253

Bibliografisk träff 2007-03-01

Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ.

Cancer Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccr.2006.12.017

Bibliografisk träff 2007-02-01

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.

Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-06-1751

Bibliografisk träff 2006-08-01

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/01.cad.0000217433.48870.37

Bibliografisk träff 2006-06-01

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.

Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN.

Clin Cancer Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-06-0793

Bibliografisk träff 2005-04-01

Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.

Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN.

Mol Cancer Ther · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-04-0293